RxDoctor Payments Data

Marty Scheinberg, MD

Urology · Chattanooga, TNNPI 1215037726

Payments from drug & device makers

$3,118in general payments, 2019–2025

Across 167 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$602
  • Astellas Pharma US Inc$389
  • Sumitomo Pharma America, Inc.$282
  • Bayer$275
  • Boston Scientific$191
  • Johnson & Johnson$185
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$3,02797%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,118 in reported general payments places this provider in the 45th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$139,673
Medicare patients
612
Services billed
3,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron15$13,486
Tamsulosin Hcl581$9,127
Silodosin49$6,344
Testosterone22$5,436
Methenamine Hippurate98$4,442
Solifenacin Succinate29$3,397
Finasteride190$2,974
Trimethoprim15$1,423
Sildenafil Citrate17$727
Testosterone Cypionate11$651
NitrofurantoinNitrofurantoin Macrocrystal21$643
Oxybutynin Chloride12$617
Alfuzosin Hcl ErAlfuzosin Hcl34$568
Bicalutamide14$543
Doxazosin Mesylate21$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$282$13,48615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 276 urology providers in Tennessee.

Other urology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →